市場調査レポート
商品コード
1462318
VIR-2218+VIR-3434の市場規模、予測、新薬の考察(2032年)VIR-2218 + VIR- 3434 Market Size, Forecast, and Emerging Insight - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
VIR-2218+VIR-3434の市場規模、予測、新薬の考察(2032年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
VIR-2218は、試験中のHBVを標的とした皮下投与のsiRNAであり、効果的な免疫反応を刺激し、HBVとHDVに対して直接的な抗ウイルス活性を有します。VIR-3218は、安定性を高め、オフターゲット活性を最小化するESC+(Enhanced Stabilization Chemistry Plus)技術を導入した臨床における最初のsiRNAであり、治療指数を高められる可能性があります。
また、VIR-3434は、HBVおよびHDVウイルスの肝細胞への侵入を阻止し、血液中のビリオンとサブウイルス粒子のレベルを低下させるように設計された試験中の皮下投与抗体です。VIR-3434は、XencorのXtendとその他のFc技術を組み込んでおり、感染患者においてHBVとHDVに対するT細胞ワクチンとして機能する可能性があり、半減期が延長するように設計されています。
当レポートでは、主要7市場(米国・ドイツ・フランス・イタリア・スペイン・英国・日本)における慢性B型肝炎向けVIR-2218+VIR-3434について調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。
"VIR-2218 + VIR- 3434 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about VIR-2218 + VIR- 3434 for chronic hepatitis B in the seven major markets. A detailed picture of the VIR-2218 + VIR- 3434 for chronic hepatitis B in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the VIR-2218 + VIR- 3434 for chronic hepatitis B. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VIR-2218 + VIR- 3434 market forecast analysis for chronic hepatitis B in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.
VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that can stimulate an effective immune response and have direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include enhanced stabilization chemistry plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index.
Also, VIR-3434 is an investigational subcutaneously administered antibody designed to block the entry of HBV and HDV viruses into hepatocytes and to reduce the level of virions and subviral particles in the blood. VIR-3434, which incorporates Xencor's Xtend and other Fc technologies, has been engineered to potentially function as a T-cell vaccine against HBV and HDV in infected patients and to have an extended half-life.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
VIR-2218 + VIR- 3434 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of VIR-2218 + VIR- 3434 for chronic hepatitis B in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2031 to 2032.
The report provides the clinical trials information of VIR-2218 + VIR- 3434 for chronic hepatitis B covering trial interventions, trial conditions, trial status, start and completion dates.